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DNA replication and recombination inhibited by anthracy-
clines. In a recent analysis of the Canadian trial NCIC CTG
MA5, which compared 6 cycles CMF (cyclophosphamide/
methotrexate/5-fluorouracil) versus CE120F (cyclophospha -
mide/epirubicin/5-fluorouracil) in 710 premenopausal women,
TOP 2A status, however, did not reach significance as a prog-
nostic factor for disease-free or overall survival [5]. The TOP
2A status can, therefore, be characterized as an interesting
area of research, but should not be assessed routinely in clini-
cal practice. The predictive value of ErbB2 overexpression for
a high responsiveness to taxanes is still a matter of debate. 
The improved clinical efficacy seen with combinations of
trastuzumab plus chemotherapy in the metastatic setting led
to the initiation of 4 large adjuvant trials with this monoclonal
antibody with a combined recruitment of more than 13,000
women with ErbB2-overxpressing early breast cancer. With
the exception of trial BCIRG 006, these trials did not combine
different cytotoxic schedules with trastuzumab. At present, it
is therefore not possible to discriminate chemotherapeutic
regimens optimally suited for the incorporation of trastuzu -
mab. On the basis of the BCIRG 006 data, however, it can be
concluded that trastuzumab can be effectively combined with
a schedule of doxorubicine/cyclophosphamide (AC), followed
by docetaxel and with carboplatin/docetaxel, with the latter
having the advantage of less cardiotoxicity [6].
Unanswered Questions in Adjuvant Trastuzumab
 Therapy
Four adjuvant trials have demonstrated the benefit of adding
trastuzumab to conventional chemotherapy in terms of im-
proving recurrence-free and overall survival [6–8]. The posi-
tive results of the first interim analyses were confirmed by
 updates of NCCTG N9831 and NSABP B-31 as well as
Introduction
Since 2001, when Sorlie et al. [1] introduced a molecular clas-
sification of breast cancer into at least 4 subgroups, the very
heterogenous prognosis of the different subtypes of this dis-
ease has been recognized. For clinical use, a more simple sub-
classification based on hormone receptor status and ErbB2
(HER2) status has been adopted, segregating hormone recep-
tor-positive breast cancer with a relatively benign prognosis,
and ErbB2-overexpressing breast tumor and triple-negative
tumors with an unfavorable clinical outcome. Women with
ErbB2-overexpressing tumors comprise up to 30% of all
breast cancer patients and are characterized by a short re-
lapse-free and overall survival [2]. The emergence of ErbB2 as
a potential target for therapy and the combination of the anti-
ErbB2 antibody trastuzumab with conventional cytotoxic
 regimens has led to a new era of breast cancer treatment [3]. 
Optimal Adjuvant Chemotherapy for  ErbB2-
Overexpressing Breast Cancer
An area of intensive investigation is the identification of sub-
sets of breast cancer patients who benefit from specific
chemotherapeutic regimens. In their pooled analysis from 7
randomized trials, Gennari et al. [4] reported a 29% reduction
in the risk of relapse and a 27% reduction in mortality for
trastuzumab-naive patients with ErbB2-overexpressing breast
tumors treated with anthracycline-based regimens compared
to the ErbB2-negative cohort. The authors concluded that the
superiority of these regimens seemed to be limited to ErbB2-
overexpressing breast cancer. The increased responsiveness of
tumors with a positive ErbB2 status to anthracyclines was
thought to be at least partially explained by coamplification of
ErbB2 and topoisomerase II alpha (TOP 2A), the enzyme for
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BCIRG 006 [9, 10]. Based on these data guidelines recom-
mending adjuvant treatment with trastuzumab for 1 year
 simultaneously with or up to 3 months after adjuvant
chemotherapy were published [11]. Nevertheless, the optimal
duration of trastuzumab treatment is still unclear. The afore-
mentioned studies have reported results with 1 year of
trastuzumab therapy. Results from the third arm of the
HERA trial, testing 2 years of trastuzumab, are not yet avail-
able and are expected in 2008. The small FinHer trial showed
an impressive relative risk reduction of 58% in disease-free
survival with only 9 weeks of trastuzumab [12]. The short du-
ration of trastuzumab therapy might be an advantage in terms
of less cardiotoxicity, as no cases of congestive heart failure
were documented in the FinHer trial. The applicability of
these results to clinical practice is, however, limited by the
small number of patients (n = 232) and few events (n = 12).
Delayed Adjuvant Treatment with Lapatinib: TEACH Trial
At present, there is a therapeutic gap for many patients with a
diagnosis of early ErbB2-overexpressing breast cancer, who
completed their primary therapy some years ago. At that time,
these women did not receive adjuvant treatment with
trastuzumab, because the results of the adjuvant trials cited
above were not yet available. Moreover, there are no data to
support the use of trastuzumab for these patients despite the
high recurrence rate in this high-risk group. 
Lapatinib is an oral receptor tyrosine kinase inhibitor (TKI) of
both ErbB1 and ErbB2 and represents an alternative anti-
ErbB2 treatment approach. On the basis of its promising activi-
ty and good tolerability in locally advanced and metastatic
breast cancer, this small molecule is now moving into early
breast cancer trials. The randomized, double-blind, multicenter,
placebo-controlled TEACH (Tykerb Evaluation After Chemo-
therapy) study is the first to analyze the efficacy of lapatinib as
delayed adjuvant therapy [13]. The aim of this phase III trial is
to determine whether lapatinib, given for 1 year, will improve
disease-free survival in women with early ErbB2-overexpress-
ing breast carcinoma. Eligible patients must have an initial diag-
nosis of confirmed breast cancer (stage I–III), completed
adjuvant chemo therapy, and no clinical or radiographic evi-
dence of disease at study entry, and will be randomized to
 lapatinib (1,500 mg daily) or placebo. This trial is currently
 recruiting but is expected to reach its recruitment goal of 3,000
patients  shortly.
Adjuvant Therapy with Lapatinib: ALTTO Trial
The current standard in the adjuvant anti-ErbB2 therapy,
trastuzumab, is challenged in the 4-arm ALTTO (Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimization) trial,
a joint effort of several international study groups. The ratio-
nale for the ALTTO trial is i) the potential development of
 resistance during or after adjuvant trastuzumab therapy; 
ii) the inability of the monoclonal antibody to cross the blood-
brain barrier under physiological circumstances; and iii) con-
cerns about the cardiac safety of trastuzumab.
In contrast to trastuzumab which prevents binding of growth
factors at the extracellular ErbB2 domain, lapatinib works by
inhibiting the intracellular tyrosine kinases of ErbB2 and
ErbB1. Lapatinib has also demonstrated activity in tumor
xenografts of p95-positive BT474 breast cancer cells that are
characterized by a truncated version of ErbB2 and to which
trastuzumab cannot bind [14]. Furthermore, lapatinib has
shown high efficacy in trastuzumab-pretreated and resistant
patients [15, 16], and has shown promising results in patients
with central nervous system (CNS) disease [17]. In preclinical
models, the addition of lapatinib to trastuzumab showed syn-
ergistic inhibitory effects on ErbB2-positive breast cancer cells
[18]. Thus, it is conceivable that the combined treatment arm
of lapatinib and trastuzumab in the ALTTO trial might offer
an improved adjuvant strategy, with increased efficacy com-
pared to each drug individually [18]. Lastly, because of the
good tolerability of lapatinib and the low incidence of left ven-
tricular ejection fraction (LVEF) decrease, this drug could
provide a better risk-benefit ratio in the adjuvant setting. 
In the ALTTO trial, patients with centrally determined early-
stage ErbB2-overexpressing breast cancer (immunohisto-
chemistry (IHC)3+ or fluorescent in situ hybridization
(FISH)+) are randomized to single-agent trastuzumab or lap-
atinib or the combination of both drugs for 1 year. In a fourth
study arm, patients are treated with trastuzumab for 3 months,
followed by lapatinib for 7.5 months after a 6-week wash-out
period (fig. 1). Eligible patients may have nodal-negative or
positive disease and must present with an LVEF of at least
50%. The primary study endpoint is disease-free survival. Sec-
ondary endpoints are overall survival, time to recurrence, time
to distant metastasis, safety and tolerability, and the cumula-
tive incidence of brain metastases as first site of recurrence. 
In ‘Design I’ of ALTTO, which is analogous to the design of
the HERA trial, patients will have completed a minimum of 4
cycles of an anthracycline-based chemotherapy with or with-
out a taxane before randomization. In ‘Design II’, the con-
comitant application of paclitaxel with the targeted therapy is
allowed after completion of the anthracycline-based therapy.
The great variability of possible chemotherapeutic regimens
reflects the fact that ALTTO, as a globally recruiting study, has
to account for different treatment patterns in the participating
countries. Accepted ‘feeder studies’ for the ALTTO trial in
Germany are: SUCCESS B, GAIN, and NNBC 3-Europe.
 Participants of these 3 trials can be randomized to one of the
ALTTO arms after completion of chemotherapy. 
A concomitant translational research program addresses criti-
cal issues, such as the clinical application of plasma proteomics
or differential gene expression and the relevance of circulating
tumor cells for the prediction of the risk of recurrence. This
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translational research will be performed at 40 selected centers
in Europe and 17 centers in the US. In total, the ALTTO trial
will recruit 8,000 patients, 2,000 of which will be part of the
translational research project. Until the end of February 2008,
about 500 patients have been included in this large adjuvant
trial, with 40% of these patients coming from Germany.
Trials with Lapatinib in the Neoadjuvant Setting 
Since its first use in the early 1970s, neoadjuvant chemothera-
py has become a standard of care for the management of lo-
cally advanced breast cancer and is increasingly used for the
treatment of early breast cancer. The aims of neoadjuvant
chemotherapy are i) downsizing of large tumors to improve
resectability; ii) achievement of pathological complete remis-
sions (pCR); and iii) providing information on the molecular
biology of tumor responses to specific cytotoxic agents. 
The meta-analysis of Mauri et al. [19], which includes 7 trials
comparing adjuvant to neoadjuvant chemotherapy, showed no
difference in recurrence-free and overall survival for patients
receiving pre- or post-operative treatment. Based on study
 results, guidelines recommend several anthracyline- and
 taxane-containing chemotherapeutic regimens for the neo -
adjuvant therapy [11]. AC regimens followed by docetaxel and
the TAC regimen with docetaxel/doxorubicin/cyclophos-
phamide are the most frequently recommended protocols. 
In patients with ErbB2-overexpressing breast cancer, trastu -
zumab can be applied as adjuvant therapy after tumor resec-
tion or concomitantly with the neoadjuvant chemotherapy. In
the trial of Buzdar et al. [20], neoadjuvant therapy with pacli-
taxel, followed by the FEC (5-fluorouracil/cyclophospha -
mide/epirubicin) regimen plus trastuzumab, yielded signifi-
cantly higher pCR rates than the same regimen without the
monoclonal antibody. 
The German GEPARDO studies have successively evaluated
different treatment regimens containing doxorubicin and do -
cetaxel in the neoadjuvant setting. GEPARQUINTO has the
aim to optimize the preoperative treatment by incorporating
different targeted agents into the neoadjuvant treatment strat-
egy. This trial has a complex design with different settings for
women with ErbB2-negative and -positive tumors and re-
sponding and non-responding patients. In the ErbB2-negative
cohort, therapy consists of the EC (epirubicin/cyclophospha-
mide) regimen followed by docetaxel/capecitabine (DX), with
or without the monoclonal anti-VEGF antibody bevacizumab.
Non-responders to EC, i.e. chemoresistant patients, are
switched to a less intensive and less toxic chemotherapy with
paclitaxel with or without an mTOR inhibitor. 
The ErbB2-positive cohort of the GEPARQUINTO trial aims
at directly comparing trastuzumab and lapatinib, each in com-
bination with the EC regimen followed by DX, in about 600
patients (fig. 2). In an interim analysis of the GEPARQUAT-
TRO trial, the simultaneous application of trastuzumab and
the EC protocol showed promising results concerning car-
Fig. 1. Design of the BIG 2.06/NCCTG N063D (ALTTO) Global Phase
III ErB2 (HER2)+ Adjuvant Trial. Design 1: Completion of all (neo) ad-
juvant chemotherapy prior to targeted therapy. Patients with ER- or PgR-
positive tumors receive endocrine therapy selected according to meno-
pausal status; endocrine therapy will be started after the end of chemo-
therapy, will be administered concurrently with targeted therapies and will
be planned for at least 5 years. Radiotherapy will be given if indicated.
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Fig. 2. GEPARQUINTO trial: study treatment in the ErbB2-positive co-
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diotoxicity with no development of congestive heart failure in
100 evaluated patients [21]. Positive results with the combina-
tion of lapatinib and paclitaxel in the neoadjuvant treatment
of inflammatory breast cancer have already been reported by
Cristofanilli et al. [22]. Thus, the application of this TKI ap-
pears to be a reasonable strategy in the preoperative setting. 
Another approach to incorporate lapatinib into current
neoadjuvant chemotherapy regimens will be investigated in
the NeoALTTO trial: In 3 study arms, lapatinib, trastuzumab,
or the combination of both anti-ErbB2 agents are adminis-
tered preoperatively in combination with paclitaxel (fig. 3).
After tumor resection, patients are treated with 3 cycles of the
FEC regimen followed by the same anti-ErbB2 therapy as in
the preoperative situation. 
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In conclusion, adjuvant chemotherapy has substantially im-
proved the prognosis of breast cancer patients with a moder-
ate or high risk of recurrence. In patients with ErbB2-overex-
pressing breast cancer, the development of agents targeted to
this receptor led to an additional progress in clinical outcome.
Trastuzumab was the first anti-ErbB2 drug successfully evalu-
ated in the adjuvant setting. The availability of lapatinib, a
dual TKI directed against 2 growth factor receptors, has the
potential to mark another step forward in the treatment of
early ErbB2-overexpressing breast cancer. Having two anti-
ErbB2 drugs with different modes of action presumably offers
the opportunity to increase efficacy by means of combination
treatments and due to the availability of alternative strategies
in the case of drug resistance.
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